FLT3 and acute myeloid leukemia: Three FLT3 inhibitors are currently FDA-approved for patients with AML: midostaurin for use in newly diagnosed FLT3-mutated AML, gilteritinib for use in relapsed or refractory FLT3-mutated AML, and quizartinib for induction, consolidation, and maintenance monotherapy.